Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seeking Broad Intervention In India, Eli Lilly Goes To Roots To Check Non-communicable Diseases

This article was originally published in The Pink Sheet Daily

Executive Summary

The Public Health Foundation of India, Project HOPE and Population Services International will be working with the company to focus on diabetes and, over time, cancer

You may also be interested in...



Rising Cases Of NCDs Prompts Indian Government To Step Up Healthcare, Screening Programs

MUMBAI - Alarmed by the rapid increase in the number of non-communicable diseases, India's ministry of health and family welfare announced that the recently unveiled National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke will be extended to the entire country over the next five years

Eli Lilly Ropes In Lupin For A Big Push For Its Insulin Brands In India

MUMBAI - As Pfizer Inc. warms up for an entry into the rapidly growing Indian insulin market, Eli Lilly & Co., which is already established in the Indian market, is looking to strengthen its franchise via a strategic collaboration with Lupin Ltd. - an Indian company making significant strides in the anti-diabetes, cardiology, nephrology and respiratory segments

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

Latest News
UsernamePublicRestriction

Register

PS072782

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel